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ABSTRACT
Objective: Timely access to necessary medicines that Aus-
tralians need is one of the four pillars of the Australian Gov-
ernment’s National Medicines Policy. We were interested to
determine whether there was a change in the time taken for
medicines to be listed once recommended by the Pharmaceu-
tical Beneﬁts Advisory Committee (PBAC).
Methods: Descriptive statistics were used to show the pat-
tern of recommendations for PBAC meetings from 1999 to
2003. For successful recommendations, we developed a lin-
ear regression model to analyze the time to list from the
PBAC meeting to date of listing (time to list). The model
determined whether this time had changed over the 4-year
period, and the reasons for any changes.
Results: The PBAC made 307 positive recommendations at
its 17 meetings over the study period. Ninety percent resulted
in a Pharmaceutical Beneﬁts Scheme (PBS) listing on or
before April 1, 2005. Eighty-two percent of the recommen-
dations made in 1999 and 2000 resulted in early or on-time
listings. In 2001, 2002, and 2003, the comparable propor-
tions were 67%, 68%, and 75%. Mean times to list for the
years from 1999 to 2003 were similar (approximately
23 weeks), except in 2001 where it was 30 weeks.
Conclusions: Over the study period, 90% of all PBAC rec-
ommendations resulted in a PBS listing. In 2001 there was a
statistically signiﬁcant increase in the mean time to list. In
addition, it appears that recommendations for new listings
and new indications (medicines that are likely to result in
substantial Government expenditure) were associated with a
longer time to list.
Keywords: cost-effectiveness, decision-making, health eco-
nomics, health policy.
Introduction
Australia has a national scheme to provide subsidized
access to necessary medicines—the Pharmaceutical
Beneﬁts Scheme (PBS). The Pharmaceutical Beneﬁts
Advisory Committee (PBAC) was established as a stat-
utory body to advise the Minister of Health and Age-
ing (Minister) on matters relating to the listing and
availability of medicines on the PBS [1]. The PBAC is
required by law to consider cost and effectiveness,
among other factors, when reviewing an application to
list a (new) medicine on the PBS (“value for money”
assessment) [2]. The PBAC has produced Guidelines
for the pharmaceutical industry on the preparation of
applications [3]. For many years, the PBAC met on a
quarterly basis. Since 2004, meetings occur three times
a year.
The PBAC makes three types of decisions
(outcomes):
• It can decide to recommend the listing of a medi-
cine on the PBS (so-called recommendation);
• It can decide not to recommend the listing of a
medicine on the PBS (rejection);
• It can defer a decision pending the provision of
speciﬁc additional information that would be rel-
evant and important to its decision (deferral).
Once a medicine has been recommended by the
PBAC, it is referred to the Pharmaceutical Beneﬁts
Pricing Authority (PBPA) for consideration. The PBPA
is a nonstatutory body that advises the Minister on
matters relating to the pricing of medicines on the PBS
[4]. The PBPA usually meets 4 to 5 weeks after each
PBAC meeting.
Recommendations are referred to the Minister, or
to Cabinet if the estimated annual cost to the PBS is
greater than AU$10 million in any of the ﬁrst 4 years
of listing, for approval. It is most unusual for a Min-
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ister not to accept a PBAC recommendation. The list-
ing process, from PBAC application to listing, takes a
minimum of 8 months. The PBS listing of a PBAC-rec-
ommended medicine can be delayed if the sponsor and
the PBPA cannot agree on price; the recommendation
is referred to Cabinet and its consideration is delayed
or deferred; or there are supply issues.
For many years PBAC decisions were not made
public. Following an agreement between the PBAC
and the pharmaceutical industry in mid-1999, all pos-
itive PBAC recommendations have been made public
since the December 1999 PBAC meeting. Further
agreement has been reached such that from its June
2003 meeting, all PBAC “decisions” (recommenda-
tions, rejections, and deferrals) will be made public,
although the extent of disclosure will be limited.
Objectives
Our aim was to determine whether, over a period of
4 years, new necessary medicines that were recom-
mended by the PBAC were made available on the PBS
in a more or less timely manner—one of the objectives
of the Government’s National Medicines Policy [5].
Our primary objective was to determine whether the
proportion of recommendations that resulted in a PBS
listing at any time varied with the year of recommen-
dation or other key variables. Our secondary objective
was to determine whether any of these variables were
associated with a prolonged time to list.
The time period of our analysis (December 1999–
December 2003) was chosen on the basis of currency
and sample size (no a priori power calculations were
conducted). Other than the introduction in June 2001
of the mandatory requirement for Cabinet approval of
recommendations that are estimated to involve consid-
erable Government expenditure, there were no new
policy/procedural initiatives that required considera-
tion during the study period [6].
Methods
We extracted the following information for each rec-
ommendation from the PBS Web site: meeting date;
(generic) name of medicine; presentation/s and
strengths; medicine use/type (indication or medicinal
class); type of listing; PBAC recommendation and
comments [7]. The information provided on medicine
type/use was used to determine the Anatomical Ther-
apeutic Chemical Classiﬁcation (ATC) system main
group for each medicine [8].
We created the following categories to classify the
recommendations by listing type:
1. New listing—a new medicine.
2. New indication—extend a current listing of a
medicine to include its subsidized use in/by a com-
pletely new patient population.
3. New combination product—a new medicine with
two or more active substances that are listed on
the PBS as individual entities.
4. Restriction change—revise the wording of the
restrictions of a listed medicine.
5. New strength—a new strength of a listed
medicine.
6. New formulation—a new presentation of a listed
medicine.
7. Therapeutic relativity—price increase for a cur-
rently listed medicine by way of a changed
(improved) therapeutic relativity.
Where a recommendation was made for more than
one listing type, we used the higher of the two catego-
ries (e.g., a new indication took precedence over a new
formulation). Information on which medicines were
referred to Cabinet for consideration was obtained
from Ministerial media releases and press articles [9].
Information on what medicines had been designated as
orphan drugs was obtained from the Register of
Orphan Drugs [10].
We classiﬁed all recommendations as being either
resolved or unresolved. The resolved recommenda-
tions were further classiﬁed as having been either
accepted or rejected by the Minister (or Cabinet).
We conﬁrmed the type of listing for all accepted rec-
ommended medicines and the date of their PBS listing
using the issues of the Schedule of Pharmaceutical Ben-
eﬁts for the period from February 1, 2000 to April 1,
2005 inclusive [11]. New issues of the Schedule were
released every 3 months during the study period. Most
listings became effective on the date of issue of the
Schedule; some became effective in between issues. The
time (in weeks) from the date of PBAC recommenda-
tion to the date of PBS listing (time to list) was
measured.
Descriptive statistics were used to determine the
proportion of recommendations made at each PBAC
meeting that achieved a PBS listing at any time. A
logistic regression model was developed to determine
whether the annual proportion was associated with
the year of recommendation (“year”) and other vari-
ables (medicine type, type of listing, Cabinet review,
and orphan drug status). “Year” was included as a cat-
egorical variable to ascertain whether there had been
any change over time in the proportion of successfully
listed recommendations. Recommendations were con-
sidered successful if they resulted in a PBS listing at any
time, regardless of the breadth of the patient popula-
tion and/or the degree of restrictions applied.
For those recommendations that resulted in a PBS
listing on or before April 1, 2005, we determined with
a further logistic regression model if the time to list
was associated with any of the variables used in the
ﬁrst model. The listing of each PBAC recommendation
was then classiﬁed as being either “early” (less than
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5 months after recommendation), “on-time” (5
months after recommendation), “late” (more than
5 months after recommendation) or “unresolved” by
comparing the actual and projected listing dates. A rec-
ommendation was considered to be “unresolved” if it
had not resulted in a listing on or before April 1, 2005.
We examined whether any of the above variables were
associated with an “early” or “on-time” listing (as
opposed to “late” or “unresolved”).
We developed a linear regression model using the
logarithm of the time to list because the distribution of
times to list in weeks was skewed; logarithmic trans-
formation reduced the distribution to approximately
normal. The regression results are presented as the
(raw) mean times to list, the geometric mean times to
list, and their 95% conﬁdence intervals (all measured
in weeks). The geometric means are found as the expo-
nential values of the “adjusted” means from the regres-
sion model (the “least squares means”). The geometric
mean is generally lower than the raw mean because it
is less inﬂuenced by outliers.
When ﬁtting the logistic regression models, we gen-
erally selected the reference category for each variable
as the largest group because this increased the stability
of the estimates. Logistic regression results are pre-
sented as odds ratios (OR) with their 95% conﬁdence
intervals. An OR greater than one indicates that rec-
ommendations made for that category were more
likely to result in a PBS listing than those made in the
reference category. All models were developed using
SAS [12]. Associations were considered to be statisti-
cally signiﬁcant if the P-value was ≤0.05.
Results
In all, there were 307 recommendations from 17
PBAC meetings, about a third of which were for new
listings (Table 1). All bar one were accepted; the rec-
ommendation to list sildenaﬁl was rejected by Cabinet
[13]. Two were made to justify the then current prices
of medicines that were already listed on the PBS and
were excluded from the analysis. The proportions of
each type of recommended listing varied little over
time.
Successful Listings over Time—All Recommendations
The annual proportions of PBAC recommendations
that resulted in successful PBS listings remained high
throughout the study period (Table 2).
The data in Table 2 reveal there were no statistically
signiﬁcant differences in the likelihood of a recommen-
dation for a new medicine to result in a listing during
the study period, despite the positive and negative
trends seen in 1999 and 2000, respectively. Only gen-
itourinary (ATC group G) and anti-infective (group J)
medicines showed a lesser chance of being listed
throughout the study period.
Analysis of Variables Associated with the Timeliness 
of Listings
The differences between years with respect to the PBS
listing of all PBAC-recommended medicines were not
signiﬁcantly different over the period (Table 3).
Recommendations that were referred to Cabinet
were signiﬁcantly more likely to either result in a
“late” listing or remain “unresolved.” Recommenda-
tions for a restriction change were less likely to result
in a “late” listing (or remain “unresolved”) than those
for a new listing. Interestingly, recommendations for
medicines in ATC groups G and J were once again
likely to be disadvantaged and result in a “late” listing
or remain “unresolved.” The reason for both of them
showing a lesser chance of being listed is unclear,
because none of them was referred to Cabinet, only
Table 1 PBAC recommendations 1999–2003
Year Total
(n)1999 2000 2001 2002 2003
PBAC meetings (n) 1* 4 4 4 4 17
Recommendations (n) 22 71 76† 59 77 305
Type of listing (%)
New listing 36 32 32 46 21 98
New indication 9 13 12 15 8 35
New combination product 18 10 8 7 4 24
Restriction change 9 8 20 14 31 55
New strength 18 20 12 8 21 48
New formulation 9 17 16 10 16 44
Therapeutic relativity 0 0 1 0 0 1
Early listings (n) 1 2 2 3 10 18
On-time listings (n) 17 56 49 37 47 206
Late listings (n) 3 4 19 12 13 51
Unresolved recommendations (n) 1 9 6† 7 7 30
*Four meetings took place in 1999, but data were only available for the last meeting.
†Excludes two recommendations.
Note the ﬁgures for the types of listing are stated in the table as proportions, not absolute numbers.
PBAC, Pharmaceutical Beneﬁts Advisory Committee.
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one (linezolid; group J) was designated as an orphan
drug, and the sample sizes were small.
Times to List for Successful Recommendations
This analysis is based on the 275 recommendations,
which resulted a PBS listing on or before April 1, 2005
(Table 4). Results from the linear regression model
showed that the variables “year” (P = 0.0038), “type
of listing” (P = 0.0332), and “orphan drug status”
(P = 0.0024) were signiﬁcantly associated with the
mean time to list. Thus, the “year” of the PBAC rec-
ommendation, the “type of listing,” and “orphan drug
status” were associated with changes in the mean time
to list over the study period. The variables “Cabinet
review” (P = 0.1188) and “medicine type” (P =
0.0523) did not reach statistical signiﬁcance.
Recommendations made in each year were similar
in their mean times to list, save that they were
extended signiﬁcantly in 2001 and were intermediate
in 2002. Pair wise comparisons also showed that the
mean time to list for 2001 was signiﬁcantly longer than
for any other year (Table 5).
In addition to these signiﬁcant differences, recom-
mendations for respiratory medicines (group R) gave a
signiﬁcantly higher mean time to list than those for
other medicine types (with all P-values less than
0.023), except for those related to alimentary (group
A) (P = 0.077), dermatological (group D) (P = 0.160),
and genitourinary (group G) medicines (P = 0.331)
(data not shown).
Recommendations for new strengths and restriction
changes took shorter times to list, and there was a
trend for those that were referred to Cabinet to take a
longer time to list, although this difference was not sig-
niﬁcant after adjustment for other variables. There
were too few recommendations for medicines in the
orphan drug category to yield data worthy of analysis
at this stage.
Unresolved Recommendations
As at April 1, 2005, there were 29 unresolved PBAC
recommendations (Table 6). In three instances, the
PBAC made further discrete recommendations (at a
later date), which resulted in their PBS listing. The pro-
portion of unresolved new listings was consistent with
the proportion of recommendations for new listings
(24% vs. 32%, respectively). Recommendations for
new anti-infective medicines (28%) and new listings
Table 2 Results from the ﬁrst logistic regression model—PBAC recommendations that resulted in a successful PBS listing on or
before April 1, 2005
Variable
Number of listings/
recommendations Odds ratio P-value 95% CI
Year of recommendation 0.477
1999 21/22 (95%) 1.29 0.83 0.13–13.12
2000 62/71 (87%) 0.39 0.13 0.11–1.33
2001 70/76 (92%) 1.08 0.91 0.30–3.94
2002 53/59 (90%) 0.85 0.81 0.23–3.12
2003 70/77 (91%) 1.0
Cabinet review 0.500
No 259/286 (91%) 1.0
Yes 17/19 (89%) 0.53 0.48 0.09–3.15
Type of listing 0.062
New listing 90/98 (92%) 1.0
New indication 33/35 (94%) 1.13 0.90 0.18–7.14
New combination product 23/24 (96%) 5.90 0.14 0.56–62.29
Restriction change 49/55 (89%) 0.49 0.29 0.13–1.84
New strength 43/48 (90%) 0.78 0.72 0.19–3.13
New formulation 37/44 (84%) 0.23 0.035 0.06–0.90
Therapeutic relativity 1/1 (100%)
Medicine type <0.001
A (alimentary) 23/25 (92%) 0.49 0.49 0.06–3.82
B (blood) 19/21 (90%) 0.34 0.30 0.04–2.68
C (cardiovascular) 33/37 (89%) 0.21 0.09 0.03–1.31
D (dermatological) 1/1 (100%)
G (genitourinary) 11/16 (69%) 0.04 0.001 0.005–0.28
H (hormone) 8/9 (89%)
J (antiinfective) 17/25 (68%) 0.06 0.001 0.01–0.32
L (antineoplastic) 35/37 (95%) 0.94 0.74 0.08–6.02
M (musculoskeletal) 24/25 (96%) 0.89 0.93 0.07–10.92
N (nervous) 52/54 (96%) 1.0
R (respiratory) 6/7 (86%)
S (sensory) 13/13 (100%)
V (various) 34/35 (97%) 2.29 0.53 0.17–29.92
D,H,R,S 28/30 (93%) 0.55 0.58 0.07–4.61
Orphan drug status 0.639
No 267/295 (91%) 1.0
Yes 9/10 (90%) 0.54 0.63 0.05–6.34
CI, conﬁdence interval; PBAC, Pharmaceutical Beneﬁts Advisory Committee; PBS, Pharmaceutical Beneﬁts Scheme.
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(57%) were the most commonly affected in terms of all
unresolved recommendations. Being referred to Cabi-
net or an orphan drug does not appear to have been a
major cause with only one in each category.
Conclusions
Timely access to the medicines that Australians need,
at a cost that individuals and the community can
afford, is one of the four pillars of the Australian Gov-
ernment’s National Medicines Policy. Our study is one
of the ﬁrst public attempts to assess the timely access to
subsidized medicines by the Australian community on
a quantitative basis. (Note the recent development of
process and impact indicators for the National Medi-
cines Policy by the Australian Pharmaceutical Advi-
sory Council [14].) We conducted our analysis on
those medicines that were recommended by the PBAC,
and were therefore considered to be necessary and cost
effective. The policy does not deﬁne “timely access” in
an absolute sense and we have not attempted to do so.
Our objective was to see whether there had been a
change in access over a 4-year period.
A reasonable expectation is that Australians should
be able to access via the PBS all new PBAC-
recommended medicines, because the Committee only
recommends those that it believes are necessary. There
is an absence of public policy and/or discussion on
what constitutes a necessary medicine and what is an
acceptable proportion of PBAC recommendations that
should result in a PBS listing (on-time or at any time).
We hope that the publication of our analysis will be the
catalyst for further public discussion and debate on
this important issue. Our analysis shows that only
90% of all PBAC recommendations for medicines
resulted in a PBS listing at any time. A total of 98
(32%) of PBAC recommendations were for new med-
icines of which 90 (92%) resulted in a PBS listing at
any time.
Furthermore, our analysis showed a statistically sig-
niﬁcant increase in the mean time to list medicines rec-
ommended in 2001. This tendency continued into
2002, albeit not signiﬁcantly. We note that the Cabinet
review process was introduced at a time when the
annual growth rate of PBS expenditure was approach-
ing 20% and the mean time to list was at its peak [15].
Table 3 Results from the second logistic regression model—comparison of late listings or unresolved recommendations to early or
on-time listings
Variable
Number of late or unresolved
listings/recommendations Odds ratio P-value 95% CI
Year of recommendation 0.162
1999 4/22 (18%) 0.53 0.34 0.14–1.97
2000 13/71 (18%) 0.57 0.22 0.24–1.39
2001 25/76 (33%) 1.51 0.32 0.68–3.36
2002 19/59 (32%) 1.06 0.89 0.45–2.49
2003 19/77 (25%) [1]
Cabinet review 0.009
No 69/286 (24%) [1]
Yes 11/19 (58%) 4.45 0.01 1.41–14.03
Type of listing 0.077
New listing 33/98 (34%) [1]
New indication 10/35 (29%) 0.98 0.96 0.36–2.65
New combination product 7/24 (29%) 0.52 0.26 0.17–1.61
Restriction change 7/55 (13%) 0.29 0.01 0.11–0.78
New strength 9/48 (19%) 0.51 0.15 0.20–1.29
New formulation 14/44 (32%) 1.16 0.74 0.49–2.75
Therapeutic relativity 0/1
Medicine type 0.035
A (alimentary) 8/25 (32%) 2.54 0.12 0.78–8.27
B (blood) 4/21 (19%) 1.25 0.76 0.31–4.98
C (cardiovascular) 12/37 (32%) 2.59 0.09 0.87–7.73
D (dermatological) 0/1 (0%)
G (genitourinary) 9/16 (56%) 7.65 0.004 1.89–30.96
H (hormone) 2/9 (22%)
J (antiinfective) 10/24 (42%) 3.86 0.02 1.23–12.13
L (antineoplastic) 8/39 (21%) 1.07 0.92 0.32–3.59
M (musculoskeletal) 6/25 (24%) 1.27 0.71 0.36–4.44
N (nervous) 9/54 (17%) [1]
R (respiratory) 6/7 (86%)
S (sensory) 1/13 (8%)
V (various) 5/34 (15%) 0.71 0.59 0.21–2.46
D,H,R,S 9/30 (30%) 1.88 0.29 0.58–6.09
Orphan drug status 0.193
No 78/295 (26%) [1]
Yes 2/10 (20%) 0.32 0.22 0.05–1.99
CI, conﬁdence interval.
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Although the reasons for the introduction of the Cab-
inet review process were not made public at the time,
we speculate that the purpose of its introduction was
to curtail growth and that it did have an inﬂuence on
the 2001 and 2002 results. Although the Cabinet
review process overall did not have a signiﬁcant effect,
it did result in substantial lengthening of the time to list
for a small number of medicines. In addition, it
appears that recommendations for new listings and
new indications; medicines that are likely to result in
substantial Government expenditure, were associated
with a longer time to list. It is our intention to continue
to monitor whether the time to list new medicines
changes with further PBS policy and procedural
enhancements.
The Department of Health and Ageing recently
commissioned an independent review of the post-
PBAC review process in collaboration with Medicines
Australia, the pharmaceutical industry’s peak body. In
a report released in July 2004 entitled “Working
together to improve the Pharmaceutical Beneﬁts
Scheme—review of the post-PBAC processes report”
are a number of recommendations that once imple-
mented may reduce the time taken for medicines to be
listed on the PBS [16]. It may be too early to determine
the impact of any of the recommended process
changes; nonetheless, the framework presented here
should serve as a useful model to measure their impact.
Because information was only available for PBAC
recommendations and not for rejections and deferrals,
we could only analyze the factors associated with suc-
cessful applications and the time taken between PBAC
recommendation and PBS listing. Because more infor-
mation is now available, we will monitor all PBAC’s
decisions (outcomes) to investigate which factors may
be associated with its recommendations. This will
include analyses of the probability of success and fail-
ure for applications to the PBAC, as well as if there are
any changes to the time taken to list those medicines
that are recommended.
Table 4 Results from the linear regression model—comparison of the mean times to list from PBAC recommendation to PBS listing.
The R2 statistic for the regression model was 30.3%
Variable
Adjusted
P-value
Mean time to
list (weeks)
Geometric
mean 95% CI
Year of recommendation 0.0038
1999 23.3 18.4 14.0–24.0
2000 22.2 18.0 14.4–22.6
2001 30.0 23.3 18.9–28.8
2002 26.7 19.8 15.9–24.9
2003 22.8 19.5 15.9–23.9
Cabinet review 0.1188
No 24.3 18.1 14.9–22.1
Yes 39.9 21.5 16.6–27.8
Type of listing 0.0332
New listing 28.9 21.8 18.3–25.8
New indication 28.1 23.2 18.8–28.6
New combination product 26.3 19.5 15.3–24.9
Restriction change 20.2 17.6 14.3–21.6
New strength 21.2 18.6 15.0–23.1
New formulation 24.8 21.3 17.2–26.3
Therapeutic relativity 21.0 16.9 7.6–37.9
Medicine type 0.0523
A (alimentary) 31.9 22.1 17.2–28.4
B (blood) 25.8 18.9 14.5–24.7
C (cardiovascular) 26.4 20.5 16.3–25.7
D (dermatological) 21.0 16.8 7.6–37.2
G (genitourinary) 33.0 25.1 18.5–34.1
H (hormone) 22.1 18.2 12.9–25.5
J (antiinfective) 22.4 17.3 13.1–22.8
L (antineoplastic) 23.4 18.2 14.7–22.5
M (musculoskeletal) 25.3 18.9 14.6–24.5
N (nervous) 22.8 17.4 13.9–21.8
R (respiratory) 40.5 30.5 21.2–43.8
S (sensory) 22.0 18.1 13.7–23.7
V (various) 23.4 18.2 14.3–23.3
Orphan drug status 0.0024
No 25.5 24.6 20.8–29.1
Yes 18.3 15.8 11.6–21.5
CI, conﬁdence interval.
Table 5 Pair-wise yearly comparisons of the mean times to list
Yearly comparison P-value
1999 vs. 2001 0.0164
2000 vs. 2001 0.0003
2002 vs. 2001 0.0282
2003 vs. 2001 0.0085
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Table 6 Unresolved recommendations
Year of
recommendation Name and presentation/s of medicine Application type
ATC 
group
Cabinet 
review
(Y/N)
Orphan 
drug
(Y/N)
1999 Epoetin alfa 500 units in 0.25 ml injections New strength B N N
2000 Clarithromycin 500 mg tablets New strength J N N
Dofetilide 125 μg, 250 μg, and 500 μg capsules New listing C N N
Repaglinide 500 μg, 1 mg, and 2 mg tablets New listing A N N
Dydrogesterone 10 mg tablets Restriction change G N N
Nevirapine 50 mg/5 ml oral suspension New formulation J N N
Piperazine oestrone sulfate + medroxyprogesterone acetate 
1.25 mg/5 mg and 1.25 mg/10 mg tablets
New combination 
product
G N N
Risperidone 0.5 mg tablets and 1 mg/ml oral solution (30 ml)† New strength N N N
Anastrozole 1 mg tablets† New indication L N N
Insulin lispro with insulin lispro protamine injection (human analog) 
100 units (50:50) per ml, 3 ml
New strength A N N
2001 Oestradiol with dydrogesterone 1 mg/5 mg tablets New formulation G N N
Enoxaparin sodium 40 μg/0.4 ml preﬁlled syringes for injection Restriction change B N N
Interferon alfa-2b 10,000,000 i.u. powder for injection with water for 
injection (diluent)—single use product
New indication L N N
Amino acid formula without phenylalanine capsules 500 g New formulation V N N
Galantamine hydrobromide 4 mg (base)/ml oral solution (100 ml) New formulation N N N
2002 Fluvastatin 80 mg prolonged release tablets New strength C N N
Mometasone 200 μg and 400 μg dry powder for inhalation New formulation R N N
Gatiﬂoxacin 400 mg tablets, 400 mg/40 ml vial, and 400 mg/20 ml infusion New listing J N N
Linezolid infusion 2 mg/ml, 600 mg tablets, and 20 mg/ml granules for 
oral suspension
New listing J N Y
Oestradiol nasal spray 150 μg per actuation† New formulation G N N
Chorionogonadotrophin alfa (rch) for injection vial with diluent New listing G N N
Naproxen 125 mg/5 ml oral suspension (500 ml) New formulation M N N
2003 Simvastatin 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg tablets Restriction change C Y N
Quinapril hydrochloride with hydrochlorothiazide 10 mg/12.5 mg and 
20 mg/25 mg tablets
New presentation C N N
Teicoplanin 400 mg powder for injection New listing J N N
Voriconazole 50 mg and 250 mg tablets and 200 mg lyophilized powder 
for solution for IV injection
New listing J N N
Gatiﬂoxacin 400 mg tablets Restriction change J N N
Progesterone 100 mg and 200 mg pessaries New formulation H N N
Voriconazole 50 mg and 200 mg powder for injection and 200 mg tablets Restriction change J N N
†Subsequently resolved after another PBAC recommendation.
ATC, Anatomical Therapeutic Chemical Classiﬁcation.
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